Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2014 Aug 5;17(4):301–309. doi: 10.1038/pcan.2014.29

Figure 6. Expression of SOX2 in human BPH and primary prostate adenocarcinoma specimens.

Figure 6

Immunohistochemical staining of SOX2 or p63 was performed on serial sections derived from BPH (A–D) or PCa (E–H) tissues. Panels A&B represented the 26 of 30 BPH cases that displayed positive SOX2 staining in basal cell layer; panels C&D represented the 4 of 30 BPH cases that showed little or no SOX2 staining but were still positive for p63. Panels E&F represented the 22 of 24 primary PCa cases that lost SOX2 expression. Some benign areas in these PCa specimens were positive for p63 but negative for SOX2 staining. Panels G&H represented cancer-adjacent normal areas in the 2 of 24 PCa cases where both p63 and SOX2 were expressed. Panels I-K are images from dual immunofluorescence staining performed on sections derived from BPH specimens. SOX2 (in green) was co-expressed with basal cell marker-p63 (in red). DAPI was used for counter-staining. Scale bars represent 25 µm.